Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LGMN | Q99538 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 1/20 | 0.37 |
| ▸ | IP6K1 | Q92551 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29681579 | 1.00 | LMNA (0.43) | LMNAMETALDH1A1KDM4EGLA | |
| SCHEMBL24532877 | 0.95 | LMNA (0.44) | LMNAMETALDH1A1KDM4EGLA | |
| SCHEMBL29681585 | 0.87 | MAPT (0.42) | LMNAMETALDH1A1KDM4EGLA | |
| SCHEMBL24532865 | 0.87 | MAPT (0.42) | LMNAMETALDH1A1KDM4EGLA | |
| SCHEMBL24532470 | 0.84 | LMNA (0.46) | LMNAALDH1A1KDM4EGLAHTT | |
| SCHEMBL29681047 | 0.84 | LMNA (0.46) | LMNAALDH1A1KDM4EGLAHTT | |
| SCHEMBL24532145 | 0.83 | IP6K1 (0.52) | LMNAALDH1A1KDM4EMEN1POLB | |
| SCHEMBL24532544 | 0.83 | MEN1 (0.47) | LMNAALDH1A1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL24532562 | 0.82 | LMNA (0.50) | LMNAALDH1A1KDM4EGLAMEN1 | |
| SCHEMBL24532531 | 0.82 | LMNA (0.47) | LMNAALDH1A1KDM4EGLAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | US | disclosed |
| WO-2022130270-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312550-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | LMNA 938/4885MET 1203/4885ALDH1A1 1593/4885 |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | FAP, PREP, CTRL | LMNA 938/4885MET 1203/4885ALDH1A1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.